Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/40313
Full metadata record
DC FieldValueLanguage
dc.contributor.authorGobe G.en
dc.contributor.authorFairlie D.en
dc.contributor.authorVesey D.en
dc.contributor.authorOwens E.en
dc.contributor.authorIyer A.en
dc.contributor.authorMorais C.en
dc.contributor.authorLohman R.en
dc.contributor.authorSuen J.en
dc.contributor.authorJohnson D.en
dc.contributor.authorNikolic-Paterson D.en
dc.date.accessioned2021-05-14T13:47:14Zen
dc.date.available2021-05-14T13:47:14Zen
dc.date.copyright2016en
dc.date.created20160927en
dc.date.issued2016-09-27en
dc.identifier.citationNephrology. Conference: 15th Asian Pacific Congress of Nephrology, APCN and 52nd ANZSN ASM. Perth, WA Australia. 21 (Supplement 2) (pp 86), 2016. Date of Publication: September 2016.en
dc.identifier.issn1320-5358en
dc.identifier.urihttps://repository.monashhealth.org/monashhealthjspui/handle/1/40313en
dc.description.abstractAim: To explore the pro-inflammatory and pro-fibrotic responses of primary human kidney tubular epithelial cells (HTECs) following activation of protease-activated receptor-2 (PAR-2) and/or the transforming growth factor-beta (TGF-beta) receptor. Background(s): Tubulointerstitial inflammation and fibrosis are observed in all progressive forms of chronic kidney disease (CKD) irrespective of the initiating insult. Recent evidence suggests that serine proteases, commonly produced following kidney injury, promote and exacerbate these responses by activating PAR-2 and TGF-beta receptors. Method(s): Confluent HTECs were treated with the synthetic PAR-2 agonist 2f-LIGRLO-NH2 (1 muM) and/or TGF-beta1 (5ng/ mL) in the presence or absence of the pan-protein kinase C (PKC) inhibitor Go6983, the TGF-beta receptor kinase inhibitor SB-431542, and PAR-2 antagonist GB88. Inductions of pro-inflammatory and pro-fibrotic molecules [e.g. CSF2, TNF-alpha, PAI- 1,MMP-1,MMP-9, and MMP-10] was measured at the mRNA and protein level by qPCR, western blot, and ELISA. Result(s): Alone, 2f-LIGRLO-NH2 significantly induced production range of molecules including CSF2, TNF-alpha, CTGF, PAI-1, MMP-1,MMP-9, and MMP-10 from HTEC. Smad2 was also activated by this treatment. TGF-beta1 treatment induced production CSF2, CTGF, and PAI-1 although to a lesser extent than with PAR-2 activation. Concurrent activation of PAR-2 and TGF-beta receptors gave a synergistic increase in the production of a number of these factors, particularly CSF2 and MMP-9. GB88, Go6983 and SB-431542 significantly reduced production of molecules CTGF, CSF2, PAI-1, and MMP-9. Conclusion(s): PAR-2 activation induces pro-inflammatory and pro-fibrotic responses in HTECs which involve PKC and TGF-beta signalling pathways. PAR-2 antagonists may be useful for pharmacotherapy of CKD, and are currently being tested for efficacy in animal models.en
dc.languageenen
dc.languageEnglishen
dc.publisherBlackwell Publishingen
dc.titleProtease activated-receptor-2 induced inflammation and fibrosis is mediated in part through activation of transforming growth factor-beta signalling.en
dc.typeConference Abstracten
dc.identifier.affiliationNephrologyen
dc.identifier.doihttp://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1111/nep.12887en
local.date.conferencestart2016-09-17en
dc.identifier.source612312633en
dc.identifier.institution(Owens, Morais, Johnson, Gobe, Vesey) Centre for Kidney Disease Research, School of Medicine, Translational Research Institute, University of Queensland, Brisbane, Australia (Iyer, Lohman, Suen, Fairlie) Division of Chemistry and Structural Biology, Institute for Molecular Bioscience, University of Queensland, Brisbane, Australia (Nikolic-Paterson) Department of Nephrology, Monash University, Monash Medical Centre, Clayton, Australiaen
dc.description.addressE. Owens, Centre for Kidney Disease Research, School of Medicine, Translational Research Institute, University of Queensland, Brisbane, Australiaen
dc.description.publicationstatusCONFERENCE ABSTRACTen
local.date.conferenceend2016-09-21en
dc.rights.statementCopyright 2016 Elsevier B.V., All rights reserved.en
dc.identifier.affiliationext(Owens, Morais, Johnson, Gobe, Vesey) Centre for Kidney Disease Research, School of Medicine, Translational Research Institute, University of Queensland, Brisbane, Australia-
dc.identifier.affiliationext(Iyer, Lohman, Suen, Fairlie) Division of Chemistry and Structural Biology, Institute for Molecular Bioscience, University of Queensland, Brisbane, Australia-
dc.identifier.affiliationmh(Nikolic-Paterson) Department of Nephrology, Monash University, Monash Medical Centre, Clayton, Australia-
item.fulltextNo Fulltext-
item.cerifentitytypePublications-
item.openairetypeConference Abstract-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
crisitem.author.deptNephrology-
Appears in Collections:Conferences
Show simple item record

Page view(s)

12
checked on Sep 14, 2024

Google ScholarTM

Check


Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.